Elevance Health, Inc. $ELV Shares Sold by Vulcan Value Partners LLC

Vulcan Value Partners LLC trimmed its holdings in Elevance Health, Inc. (NYSE:ELV) by 7.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 386,214 shares of the company’s stock after selling 32,981 shares during the period. Elevance Health accounts for about 2.4% of Vulcan Value Partners LLC’s holdings, making the stock its 13th biggest holding. Vulcan Value Partners LLC owned 0.17% of Elevance Health worth $135,424,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Syverson Strege & Co grew its holdings in Elevance Health by 9.4% in the 4th quarter. Syverson Strege & Co now owns 734 shares of the company’s stock valued at $257,000 after buying an additional 63 shares in the last quarter. Unison Asset Management LLC grew its holdings in Elevance Health by 7.0% in the 4th quarter. Unison Asset Management LLC now owns 27,745 shares of the company’s stock valued at $9,704,000 after buying an additional 1,824 shares in the last quarter. Kestra Investment Management LLC purchased a new stake in Elevance Health in the 4th quarter valued at $363,000. Harbour Investments Inc. grew its holdings in Elevance Health by 67.9% in the 4th quarter. Harbour Investments Inc. now owns 2,819 shares of the company’s stock valued at $988,000 after buying an additional 1,140 shares in the last quarter. Finally, Allstate Corp grew its holdings in Elevance Health by 100.6% in the 4th quarter. Allstate Corp now owns 16,837 shares of the company’s stock valued at $5,902,000 after buying an additional 8,445 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV opened at $391.00 on Thursday. The stock’s 50-day moving average price is $339.83 and its 200 day moving average price is $337.98. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $408.00. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $84.91 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 2.20 and a beta of 0.66.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the prior year, the company earned $11.97 EPS. Elevance Health’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts expect that Elevance Health, Inc. will post 26.91 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.8%. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Bank of America upgraded Elevance Health from a “neutral” rating to a “buy” rating and upped their target price for the company from $405.00 to $435.00 in a report on Wednesday, April 29th. UBS Group upped their target price on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Barclays upped their target price on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a report on Tuesday. Sanford C. Bernstein upped their target price on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a report on Friday, April 24th. Finally, Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $403.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.